Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension (UMOD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03354897
Recruitment Status : Recruiting
First Posted : November 28, 2017
Last Update Posted : August 12, 2020
Sponsor:
Collaborators:
University of Glasgow
British Heart Foundation
Information provided by (Responsible Party):
NHS Greater Glasgow and Clyde

Brief Summary:
The hypothesis is based on UMOD rs13333226 genotype, there are two strata of hypertensive patients. The High-UMOD group (AA genotype) has increased UMOD excretion, greater salt sensitivity, HTN, normal eGFR and greater BP response to loop diuretics like furosemide. The Low-UMOD group (G allele) has decreased UMOD excretion, salt resistance, increased eGFR, increased proximal tubular reabsorption of Na (possibly related to increased GFR), a poor BP response to loop diuretics, and possibly diminished function of NKCC2. The High-UMOD strata will have decreased delivery of Na+ to the distal tubule and collecting duct because NKCC2 function is normal and the study hypothesis is that the participants will be more responsive to loop diuretics. In contrast, the Low-UMOD group (G allele) will not show a similar response to loop diuretics. This may be related either to lower Na delivery to the TAL, because of increased proximal tubular reabsorption of Na+, or a suppressed function of NKCC2. The population distribution of the High-UMOD group (AA) is 67%. Our overall objective is to test the hypothesis that hypertensive subjects with uncontrolled HTN open possessing the AA genotype of rs13333226 will be better responders to loop diuretics compared to those possessing the G allele.

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Hypertension Drug: Torasemide 5Mg Tablet Phase 4

Detailed Description:

There are over 1 billion people with HTN worldwide, and the World Health Organisation suggests this will rise to 1.5 billion by 2020.(1) Up to 30% of hypertensive patients have resistant HTN (uncontrolled BP on > 3 drugs of which one must be a diuretic) and ~50% have uncontrolled HTN, with a 7-fold higher cardiovascular risk.

In clinical practice, criteria such as ancestry and serum renin levels provide only a rough indication of the underlying disease pathway and, while pharmacotherapy is the mainstay of HTN management, the selection of antihypertensive therapy is essentially by trial-and-error. Five drug classes are the main first-line agents for HTN, but response rates to any given drug are only ~50%. There are no new anti-hypertensive drugs in clinical trials and there is a need to either develop newer agents or target existing drugs to specific strata of hypertensive patients in whom they would be beneficial. The recent failure of the Renal Sympathetic Denervation trial, which used a novel device strategy for resistant HTN, highlights the limited options available in the management of uncontrolled or resistant HTN.

HTN as a phenotype demonstrates stratification in the population, based on the specific pathophysiological and molecular pathways that are operative and this is reflected in the current NICE guidelines. However, there has been little progress in stratification by leveraging genomic and molecular information, although there is evidence that this may be useful. Monogenic forms of HTN show that identification of the many causative mutations, primarily affecting the kidney and sodium balance, can inform therapy - for example, glucocorticoids in glucocorticoid remediable aldosteronism and amiloride in Liddle syndrome. Despite the successful adoption of the BHS/NICE treatment algorithm for the treatment of HTN, there remains substantial clinical uncertainty about the preferred clinical management of people with uncontrolled or treatment resistant HTN. Moreover, the choice of diuretic, suggested in HTN guidelines, is not based on clinical trials for third line antihypertensive agents. There is general consensus that resistant HTN is due to excessive sodium retention and thus "further diuretic therapy" may be an effective treatment. The choice that one type of diuretic will be superior to another has however not been studied and is usually prescribed in a trial and error manner with diuretics that primarily target the distal nephron (thiazide-like diuretic or spironolactone).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This study is a multi-centre prospective cohort study to investigate whether individuals possessing the AA genotype of the single nucleotide polymorphism, rs13333226, are better responders to loop diuretics compared to those possessing the G allele.
Masking: None (Open Label)
Masking Description: prospective cohort study
Primary Purpose: Treatment
Official Title: Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension
Actual Study Start Date : April 5, 2017
Estimated Primary Completion Date : August 15, 2021
Estimated Study Completion Date : August 25, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sodium

Arm Intervention/treatment
Treatment
16 weeks treatment 5mg/day
Drug: Torasemide 5Mg Tablet
16 weeks treatment




Primary Outcome Measures :
  1. Change in ABPM [ Time Frame: 16 weeks ]
    Change in 24h ABPM systolic BP AUC at the end of the 16-week treatment phase compared to baseline


Secondary Outcome Measures :
  1. change in 24h ABPM diastolic BP AUC [ Time Frame: 16 weeks ]
    change in 24h ABPM diastolic BP AUC between baseline and the end of treatment

  2. change in day time ABPM systolic and diastolic BP AUC [ Time Frame: 16 weeks ]
    change in day time ABPM systolic and diastolic BP AUC between baseline and the end of treatment

  3. change in night time ABPM systolic and diastolic BP AUC [ Time Frame: 16 weeks ]
    change in night time ABPM systolic and diastolic BP AUC between baseline and the end of treatment

  4. change in HBPM SBP and DBP AUC [ Time Frame: 16 weeks ]
    change in HBPM SBP and DBP AUC over the entire study period

  5. changes in serum electrolytes [ Time Frame: 16 weeks ]
    changes in serum electrolytes over the entire study period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hypertensive patients aged ≥18 years of age
  • Patients will all have hypertension that is not controlled to home target: SBP >135 mmHg and/or DBP >85 mmHg on therapy with one or more antihypertensive drugs for at least 3 months.
  • Able to attend one of the three study centres

Exclusion Criteria:

  • Inability to give informed consent
  • Participation in a clinical study involving an investigational drug or device within 3 months of screening
  • Secondary or accelerated hypertension (investigator opinion)
  • Diabetes mellitus (Type 1 or type 2)
  • eGFR <60 mls/min, hyponatraemia, hypokalaemia
  • Pregnancy, breast feeding
  • Women of child bearing potential who are unwilling to use effective contraception
  • Childbearing potential is defined as women who have experienced menarche and who have not undergone successful surgical sterilisation or who are not post-menopausal (irregular menstrual periods, or amenorrhoea >12 months, with serum follicle stimulating hormone (FSH) >35mIU/ml; women taking hormone replacement therapy (HRT)
  • Women of childbearing potential will be eligible if they are willing to use acceptable contraception (combined oral contraceptives, progesterone only contraceptives, intrauterine device, barrier methods) or they are abstinence due to lifestyle choice or their partner is sterile (vasectomy).
  • Anticipated change of medical status during the trial (e.g. surgical intervention requiring >2 weeks convalescence)
  • Recent (<6 months) cardiovascular event requiring hospitalisation (e.g. myocardial infarction or stroke)
  • Requirement for study drug or other loop diuretic for reason other than to treat hypertension
  • Clinically relevant contra-indication to treatment with torasemide: hypersensitivity, hereditary problems of glucose intolerance, Lapp lactase deficiency of glucose-galactose malabsorption
  • Current therapy for cancer
  • Concurrent chronic illness, or other reasons likely to preclude 18-week participation in the study
  • Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug or severely limit that patients life-span or ability to complete the study (e.g. alcohol or drug abuse, disabling or terminal illness, severe liver impairment, mental disorders)
  • Treatment with any of the following medications -
  • Oral corticosteroids within 3 months of screening. Treatment with systemic corticosteroids is also prohibited during study participation
  • Chronic stable use, or unstable use of NSAIDs (other than low dose aspirin or occasional OTC analgesic doses) is prohibited. Chronic use is defined as >3 consecutive days of treatment per week. In addition intermittent use of NSAIDs is discouraged throughout the study. For those requiring analgesics during the study, paracetamol or opiate drugs are recommended.
  • Use of lithium
  • Participants on the following medications may be included provided they meet the following criteria
  • Use of thiazide or loop diuretics prior to the study if the diuretic can be stopped for 2 weeks (washout) before the study medication administered.
  • The use of short acting nitrates (e.g. sublingual nitroglycerin) is permitted. However, participants should avoid short acting oral nitrates within 4 hours of screening or an subsequent visit
  • The use of long acting nitrates (e.g. Isordil) is permitted but the dose must be stable for at least 2 weeks prior to screening and randomisation
  • The use of sympathomimetic decongestants is permitted, though not within 24 hours of any study visit/BP assessment
  • The use of theophylline is permitted but the dose must be stable for at least 4 weeks prior to screening and throughout the study
  • The use of phosphodiesterase type V inhibitors is permitted. However, study participants must refrain from taking these medications for at least 7 days prior to screening or any subsequent study visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03354897


Contacts
Layout table for location contacts
Contact: Katriona JM Brooksbank, PhD 0141 330 2627 ext 2627 katriona.brooksbank@glasgow.ac.uk
Contact: Linsay McCallum, MbChB 0141 330 7397 linsay.mccallum@glasgow.ac.uk

Locations
Layout table for location information
United Kingdom
Glasgow Clinical Research Facility Recruiting
Glasgow, United Kingdom, G51 4TF
Contact: Hayley King, RCN    0141 232 7600    hayley.king@ggc.scot.nhs.uk   
Contact: Ammani Brown, RCN    0141 232 7600    ammani.brown@ggc.scot.nhs.uk   
Sponsors and Collaborators
NHS Greater Glasgow and Clyde
University of Glasgow
British Heart Foundation
Investigators
Layout table for investigator information
Study Chair: Sandosh Padmanabhan, MbChB PhD University of Glasgow
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: NHS Greater Glasgow and Clyde
ClinicalTrials.gov Identifier: NCT03354897    
Other Study ID Numbers: GN14CE400
First Posted: November 28, 2017    Key Record Dates
Last Update Posted: August 12, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by NHS Greater Glasgow and Clyde:
stratified medicine, UMOD, torasemide
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Cardiovascular Diseases
Vascular Diseases
Torsemide
Antihypertensive Agents
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action